sporad
human
infect
avian
influenza
virus
rais
concern
reassort
human
avian
subtyp
could
gener
virus
pandem
potenti
vaccin
princip
mean
combat
impact
influenza
influenza
pandem
immun
statu
popul
would
differ
exist
interpandem
period
emerg
pandem
viru
creat
surg
worldwid
vaccin
demand
new
approach
immunis
strategi
may
need
ensur
optimum
protect
unprim
individu
vaccin
antigen
may
limit
manufactur
vaccin
pathogen
avian
influenza
virus
tradit
method
feasibl
safeti
reason
well
technic
issu
strategi
adopt
overcom
issu
includ
use
revers
genet
system
gener
reassort
strain
use
baculovirusexpress
haemagglutinin
relat
nonpathogen
avian
influenza
strain
use
adjuv
enhanc
immunogen
clinic
trial
convent
surfaceantigen
influenza
viru
vaccin
produc
avian
virus
prove
poorli
immunogen
immunolog
naiv
popul
adjuv
wholeviru
prepar
may
improv
immunogen
allow
spare
antigen
infecti
diseas
caus
huge
annual
toll
morbid
mortal
econom
loss
influenza
addit
influenza
unpredict
emerg
caus
pandem
spanish
pandem
spread
around
world
within
month
caus
million
death
transmiss
avian
influenza
least
peopl
asian
epizoonot
period
prompt
concern
next
pandem
immin
highlight
recent
sever
acut
respiratori
syndrom
sar
coronaviru
outbreak
intern
air
travel
increas
global
vulner
infecti
respiratori
pathogen
abil
combat
influenza
complic
depend
primarili
vaccin
annual
influenza
vaccin
product
wellplan
process
take
month
current
facil
may
suitabl
rapid
bulk
manufactur
avian
influenza
viru
vaccin
respons
world
threat
influenza
virus
envelop
negativesens
rna
virus
segment
genom
belong
orthomyxovirida
famili
classifi
basi
core
protein
three
distinct
type
b
c
influenza
virus
infect
rang
mammalian
avian
speci
wherea
type
b
c
essenti
restrict
human
be
influenza
virus
respons
annual
epidem
occasion
pandem
wherea
influenza
b
virus
caus
outbreak
everi
year
associ
pandem
main
antigen
determin
influenza
b
virus
two
surfac
glycoprotein
neuraminidas
haemagglutinin
capabl
elicit
immun
respons
human
be
haemagglutinin
involv
receptor
bind
membran
fusion
neuraminidas
facilit
cleavag
viru
progeni
infect
cell
prevent
viral
aggreg
aid
movement
mucos
respiratorytract
epithelium
viru
strain
classifi
accord
host
speci
origin
geograph
site
year
isol
serial
number
influenza
serolog
properti
subtyp
haemagglutinin
neuraminidas
influenza
subtyp
circul
human
be
evolv
undergo
antigen
variabl
continu
lack
effect
proofread
viral
rna
polymeras
lead
high
rate
transcript
error
result
aminoacid
substitut
surfac
glycoprotein
viru
variant
substitut
antibodybind
site
evad
humor
immun
reinfect
individu
term
antigen
drift
segment
viral
genom
allow
second
type
antigen
variat
two
influenza
virus
simultan
infect
host
cell
genet
reassort
may
gener
novel
viru
new
surfac
intern
protein
pandem
influenza
virus
aris
process
antigen
shift
viru
new
haemagglutinin
subtyp
emerg
spread
effici
naiv
human
popul
comparison
pandem
interpandem
influenza
shown
tabl
bird
popul
avian
influenza
virus
gener
caus
diseas
natur
host
princip
site
influenza
viru
replic
aquat
bird
gastrointestin
tract
result
high
faecal
viral
titr
viral
transmiss
migratori
feed
area
despit
rang
viru
subtyp
haemagglutinin
neuraminidas
subtyp
establish
human
be
caus
widespread
respiratori
diseas
haemagglutinin
human
influenza
virus
preferenti
bind
sialic
acid
receptor
contain
linkag
wherea
avian
influenza
virus
preferenti
bind
contain
linkag
bind
prefer
correl
predomin
sialic
acid
linkag
human
epitheli
cell
linkag
avian
intestin
epitheli
cell
although
molecular
mechan
respons
receptorbind
specif
poorli
defin
believ
haemagglutinin
avian
origin
must
acquir
human
receptorbind
specif
gener
influenza
strain
capabl
sustain
humantohuman
transmiss
sitedirect
mutagenesi
studi
shown
one
two
aminoacid
mutat
requir
chang
limit
passag
human
be
viru
possess
avian
haemagglutinin
occur
asia
current
may
suffici
gener
chang
centuri
viru
viru
viru
caus
influenza
pandem
humanavian
reassort
virus
seem
caus
pandem
viru
differ
three
gene
haemagglutinin
neuraminidas
rna
polymeras
viru
infect
peopl
viru
differ
two
gene
haemagglutinin
viru
infect
peopl
case
haemagglutinin
gene
contribut
avian
virus
sequenc
analys
earli
isol
indic
receptorbind
specif
alter
singl
aminoacid
substitut
soon
human
introduct
sinc
pig
trachea
contain
receptor
avian
human
influenza
virus
support
replic
virus
human
avian
origin
suggest
genet
reassort
avian
swine
human
influenza
virus
may
occur
pig
repres
mix
bowl
evolut
human
pandem
strain
haemagglutinin
neuraminidas
virus
isol
human
be
poultri
wild
duck
distinguish
properti
chicken
seem
support
separ
natur
reservoir
influenza
virus
indic
possibl
role
intermedi
host
zoonot
transmiss
avian
virus
establish
poultri
capabl
twoway
transmiss
domest
duck
abl
gener
multipl
reassort
cocircul
virus
reassort
virus
haemagglutinin
receptorbind
sequenc
potenti
capabl
human
infect
suggest
new
virus
may
emerg
directli
avian
pool
close
proxim
peopl
high
concentr
waterfowl
poultri
swine
southeast
asia
avian
influenza
activ
identifi
region
hypothet
influenza
epicentr
figur
avian
influenza
virus
gener
replic
effici
human
be
even
experiment
infect
direct
transmiss
avian
influenza
virus
human
respiratori
system
consid
possibl
howev
recognis
least
subtyp
avian
influenza
virus
replic
within
human
respiratori
tract
although
unclear
whether
recent
report
increas
transmiss
avian
influenza
peopl
tabl
result
heighten
surveil
geograph
expans
poultri
outbreak
across
asia
unpreced
new
event
confirm
case
transmiss
avian
viru
human
be
increas
possibl
avianhuman
reassort
viru
may
emerg
effect
transmit
among
peopl
caus
immun
popul
result
pandem
influenza
antigen
shift
emerg
novel
littl
background
immun
high
attack
rate
excess
mortal
reemerg
subtyp
influenza
mayb
partial
immun
older
morbid
age
group
peopl
reemerg
viru
interpandem
influenza
antigen
drift
evolut
exist
littl
immun
infant
partial
variabl
outbreak
epidem
influenza
b
strain
immun
adult
crossreact
variabl
morbid
antibodi
previous
seen
mortal
usual
elderli
young
relat
strain
greatest
sever
first
associ
avian
influenza
virus
respiratori
ill
human
be
six
death
human
case
highli
pathogen
influenza
occur
outbreak
among
livebird
market
tabl
viral
gene
avian
origin
indic
cross
speci
barrier
without
adapt
reassort
human
virus
despit
elimin
duck
gees
quail
sourc
donor
gene
clean
day
market
virus
subsequ
reemerg
hong
kong
poultri
market
although
hong
kong
remain
free
infect
outbreak
across
asia
late
highli
pathogen
virus
isol
dead
waterfowl
hong
kong
person
commun
peiri
univers
hong
kong
notabl
sinc
virus
typic
caus
diseas
waterfowl
februari
reemerg
hong
kong
two
famili
member
return
trip
china
pathogen
virus
caus
extens
poultri
outbreak
asia
death
human
case
report
vietnam
thailand
hong
kong
influenza
virus
isol
children
mild
respiratori
ill
humantohuman
transmiss
evid
addit
human
infect
china
detect
antibodi
human
serum
sampl
china
hong
kong
suggest
human
infect
occur
eurasian
virus
circul
sinc
late
classifi
three
phylogenet
sublineag
establish
livebird
also
transmit
swine
hong
kong
china
avian
virus
acquir
receptorbind
characterist
typic
human
strain
increas
potenti
reassort
within
human
pig
respiratori
tract
earli
outbreak
highli
pathogen
avian
influenza
among
poultri
occur
netherland
extend
belgium
germani
worker
involv
control
outbreak
develop
viral
conjunct
develop
respiratori
ill
evid
limit
humantohuman
spread
fatal
respiratori
infect
highlight
signific
threat
human
health
recent
case
avian
influenza
infect
report
two
culler
control
poultri
outbreak
canada
avian
influenza
seem
cross
speci
barrier
poultri
peopl
first
time
egypt
april
two
infant
present
mild
febril
respiratori
symptom
influenza
virus
isol
respiratori
sampl
well
virus
subtyp
acquir
abil
infect
chicken
rapidli
becom
endem
poultri
popul
phylogenet
analys
virus
isol
wildfowl
show
high
nucleotid
homolog
intern
gene
human
virus
suggest
subtyp
transfer
genet
materi
potenti
sourc
new
strain
virus
respons
influenza
pandem
circul
human
subtyp
replac
subtyp
haemagglutinin
gene
along
neuraminidas
gene
deriv
avian
sourc
sinc
peopl
born
lack
immun
subtyp
virus
pose
pandem
threat
suscept
popul
virus
continu
circul
wild
duck
although
condit
requir
reemerg
human
influenza
virus
unclear
although
virul
avian
influenza
virus
well
studi
avian
speci
virul
mammal
well
understood
infect
avian
influenza
virus
bird
caus
wide
spectrum
diseas
rang
subclin
overwhelm
system
ill
figur
subtyp
abil
evolv
highli
pathogen
form
although
virul
polygen
trait
major
contribut
factor
bird
haemagglutinin
cleavag
haemagglutinin
two
subunit
essenti
viral
infect
haemagglutinin
strain
low
pathogen
cleav
proteas
limit
respiratori
tract
mammalian
speci
intestin
tract
avian
speci
contrast
haemagglutinin
highli
pathogen
virus
cleav
proteas
present
rang
tissu
result
multisystem
infect
structur
featur
cleavag
site
determin
cleavabl
haemagglutinin
acquisit
multipl
basic
aminoacid
highli
pathogen
haemagglutinin
enabl
cleavag
protein
ubiquit
proteas
confer
virul
carbohydr
side
chain
vicin
cleavag
site
may
also
affect
access
proteas
henc
virul
factor
addit
haemagglutinin
cleavag
site
like
contribut
viru
pathogen
mammal
virul
mouseadapt
influenza
virus
associ
interferon
antagonist
properti
protein
abil
neuraminidas
glycoprotein
sequest
circul
plasminogen
promot
haemagglutinin
cleavag
balbc
mice
ferret
use
mammalian
host
evalu
human
pathogenesi
mammalian
host
multibas
aminoacid
motif
haemagglutinin
necessari
suffici
virul
singl
aminoacid
substitut
associ
high
pathogen
human
virus
mice
although
substitut
gene
product
like
play
part
human
infect
diseas
progress
respiratori
failur
unusu
sever
featur
haemophagocytosi
leucopenia
multipl
organ
failur
invitro
infect
human
macrophag
human
virus
induc
high
level
cytokin
compar
human
viru
strain
pig
respiratori
epitheli
cell
human
virus
also
shown
rel
resist
inhibitori
effect
host
antivir
cytokin
interferon
thu
sever
infect
peopl
like
relat
induct
excess
proinflammatori
respons
exacerb
tissu
injuri
suggest
nonstructur
gene
role
gene
sequenc
analys
pandem
viru
display
enhanc
virul
human
be
yet
uncov
molecular
determin
previous
associ
influenza
viru
virul
molecular
determin
gene
constel
confer
virul
avian
swine
human
virus
circumst
virul
phenotyp
emerg
remain
unclear
understand
basi
virul
import
vaccin
design
particularli
live
vaccin
virus
attenu
current
inactiv
influenza
vaccin
produc
viru
grown
embryon
hen
egg
three
type
wholeviru
splitproduct
subunit
surfaceantigen
formul
wholeviru
vaccin
associ
increas
advers
reaction
especi
children
littl
use
influenza
vaccin
splitproduct
vaccin
produc
detergenttr
highli
purifi
influenza
viru
surfaceantigen
vaccin
contain
purifi
haemagglutinin
neuraminidas
vaccin
usual
trival
contain
g
two
influenza
subtyp
one
influenza
b
strain
vaccin
elicit
rel
strainspecif
humor
respons
reduc
efficaci
antigen
drift
virus
ineffect
unrel
strain
review
vaccin
composit
biannual
updat
antigen
content
depend
preval
circul
subtyp
provid
antigen
wellmatch
vaccin
protect
efficaci
healthi
young
adult
obtain
good
antigen
match
vaccin
circul
strain
vaccin
elderli
associ
reduct
hospitalis
pneumonia
influenza
reduct
respiratori
condit
reduct
allcaus
mortal
new
influenza
vaccin
must
elicit
protect
immun
haemagglutinininhibit
test
commonli
use
detect
antibodi
influenza
although
singl
radial
haemolysi
srh
may
also
use
sinc
correl
immun
protect
european
union
interpandem
influenza
vaccin
fulfil
certain
criteria
prepar
committe
proprietari
medicin
product
cpmp
usual
assess
haemagglutinininhibit
test
limit
annual
clinic
studi
panel
event
pandem
influenza
vaccin
demand
would
soar
save
made
use
monoval
rather
trival
vaccin
g
haemagglutinin
per
dose
instead
g
would
possibl
offset
twodos
schedul
increas
demand
difficulti
product
egggrown
virus
new
develop
includ
use
mammalian
cell
line
cultur
influenza
viru
vaccin
provid
increas
flexibl
product
time
heighten
demand
immunopotenti
effect
adjuv
wholeviru
vaccin
may
increas
antigen
allow
dose
content
reduct
enabl
maximum
effici
use
limit
suppli
popul
immun
statu
pandem
situat
differ
seen
interpandem
period
onset
previou
pandem
younger
adult
immunolog
naiv
new
strain
wherea
older
popul
may
prime
previou
infect
relat
strain
circul
earlier
time
global
immun
suscept
avian
influenza
subtyp
would
expect
quantiti
antigen
requir
elicit
satisfactori
immun
respons
naiv
individu
unclear
sinc
studi
done
emerg
novel
viru
current
event
suggest
urgent
need
develop
clearli
defin
strategi
clinic
assess
safeti
immunogen
pandem
vaccin
emerg
influenza
anew
trigger
pandem
alert
afford
opportun
vaccin
trial
immunolog
naiv
prime
popul
seri
wholeviru
vaccin
studi
report
differ
naiv
popul
age
year
expos
previou
strain
prime
popul
older
naiv
patient
one
dose
vaccin
administ
larg
dose
excess
g
haemagglutinin
requir
fulfil
cpmp
criteria
howev
two
dose
vaccin
given
lower
antigen
dose
g
need
wholeviru
vaccin
significantli
immunogen
subunit
splitproduct
vaccin
prime
patient
case
interpandem
period
differ
immunogen
wholeviru
vaccin
subunit
splitproduct
vaccin
report
howev
consist
find
wholeviru
vaccin
associ
increas
reactogen
particularli
children
develop
febril
complic
even
low
dose
although
licens
use
human
influenza
vaccin
aluminium
salt
rare
use
sinc
studi
indic
littl
clinic
benefit
howev
encourag
find
recent
report
studi
wholeviru
vaccin
immunolog
naiv
peopl
monoval
alumadjuv
vaccin
contain
either
g
haemagglutinin
per
dose
compar
unadjuv
wholeviru
g
vaccin
although
singl
dose
vaccin
unabl
elicit
respons
associ
protect
second
dose
vaccin
boost
respons
mean
geometr
increas
antibodi
year
group
number
seroconvers
signific
rise
antihaemagglutinin
antibodi
ie
fourfold
increas
postvaccin
hi
titr
increas
srh
zone
year
group
proport
patient
achiev
seroprotect
hi
titr
srh
titr
mm
post
vaccin
year
group
rate
fulfil
cpmp
licens
criteria
across
dose
suggest
eightfold
reduct
antigen
content
could
achiev
addit
alum
figur
sinc
influenza
virus
possess
segment
genom
simultan
infect
egg
two
differ
virus
may
result
reassort
segment
produc
desir
vaccin
seed
strain
influenza
viru
compon
annual
influenza
vaccin
typic
deriv
egggrown
reassort
virus
relev
haemagglutinin
neuraminidas
gene
antigen
relev
strain
six
remain
gene
segment
apuerto
segment
confer
high
growth
properti
egg
favour
inactiv
vaccin
product
process
requir
larg
number
egg
mani
compani
lack
flexibl
respond
rapidli
pandem
event
highli
pathogen
virus
grown
larg
quantiti
lethal
chicken
embryo
pathogen
strain
also
impos
regulatori
safeti
issu
multibas
sequenc
cleavag
site
believ
contribut
pathogenesi
human
infect
vaccin
prepar
wildtyp
viru
would
requir
heighten
biocontain
protect
worker
elimin
possibl
environment
contamin
infect
suscept
anim
thu
sever
approach
attempt
avian
influenza
vaccin
develop
includ
product
inactiv
vaccin
wildtyp
viru
select
antigen
relat
nonpathogen
vaccin
strain
use
baculovirus
express
recombin
haemagglutinin
dnabas
vaccin
use
plasmidbas
revers
genet
system
construct
vaccin
seed
strain
possess
attenu
haemagglutinin
plasmidbas
revers
genet
system
construct
attenu
donor
strain
recombin
revers
genet
like
produc
rapid
respons
emerg
pandem
much
preclin
clinic
develop
highli
pathogen
avian
influenza
vaccin
use
viru
model
outbreak
inactiv
vaccin
wildtyp
ahong
viru
prepar
uk
netherland
wholeviru
vaccin
effect
protect
mice
lethal
challeng
viru
convent
surfaceantigen
vaccin
poorli
immunogen
chicken
protect
lethal
dose
challeng
although
iscom
formul
antigen
immunecomplex
stimul
boost
immun
respons
protect
lethal
challeng
use
highli
pathogen
strain
safeti
restrict
select
surrog
nonpathogen
viru
capabl
evok
crossreact
immun
hong
kong
virus
investig
aduckhokkaido
haemagglutinin
protein
antigen
similar
ahong
kong
use
experiment
vaccin
although
antibodi
titr
induc
aduck
singapor
vaccin
fourfold
lower
homolog
strain
inactiv
wholeviru
vaccin
alumadjuv
subunit
vaccin
capabl
protect
mice
lethal
challeng
although
attempt
reassort
aducksingapor
produc
highgrowth
viru
suitabl
vaccin
product
fail
convent
aduck
surfaceantigen
vaccin
clinic
assess
randomis
phase
trial
two
dose
g
haemagglutinin
given
week
apart
antibodi
respons
measur
haemagglutinininhibit
viru
microneutralis
srh
although
vaccin
well
toler
nonadjuv
vaccin
poorli
immunogen
one
recipi
seroconvert
haemagglutinininhibit
srh
four
microneutralis
srh
two
g
dose
addit
gave
significantli
higher
antibodi
respons
figur
two
dose
achiev
seroconvers
rate
haemagglutinininhibit
microneutralis
srh
srh
respect
antibodi
titr
srh
half
show
need
close
antigen
match
vaccin
pandem
strain
ensur
maximum
vaccin
efficaci
antibodi
respons
revaccin
month
later
boost
significantli
achiev
two
dose
desir
vaccin
boost
respons
initi
prime
sinc
second
wave
occur
month
first
pandem
wave
infect
one
problem
assess
vaccin
respons
insensit
haemagglutinininhibit
test
routin
use
assess
influenza
vaccin
detect
antibodi
compar
neutralis
test
haemagglutinininhibit
reli
abil
antibodi
disrupt
haemagglutininsialicacidreceptor
bind
interact
viru
erythrocyt
erythrocyt
use
test
optimis
express
linkag
necessari
avian
influenza
viru
bind
test
insensit
howev
recognis
clinic
correl
immun
protect
neutralis
antibodi
possibl
assess
vaccin
respons
respect
cpmp
licens
criteria
develop
specif
srh
assay
modifi
haemagglutinininhibit
test
use
enzymat
alter
turkey
erythrocyt
hors
erythrocyt
develop
increas
sensit
detect
antibodi
avian
influenza
viru
antigen
altern
eggderiv
vaccin
involv
use
haemagglutinin
protein
express
insect
cell
recombin
baculoviru
potenti
difficulti
includ
use
uncleav
rather
cleav
haemagglutinin
differ
glycosyl
insect
cell
may
effect
immunogen
nonetheless
antibodi
respons
g
dose
recombin
antigen
similar
induc
licens
vaccin
baculovirusderiv
haemagglutinin
vaccin
protect
lethal
viru
challeng
chicken
even
haemagglutinin
sequenc
homolog
differ
howev
clinic
assess
peopl
recombin
baculovirusexpress
vaccin
suboptim
even
two
dose
g
subject
seroconvert
microneutralis
suggest
improv
immunogen
need
revers
genet
system
use
gener
attenu
avian
influenza
virus
like
prove
pivot
pandem
vaccin
develop
appropri
haemagglutinin
neuraminidas
gene
viru
clone
necessari
haemagglutinin
may
attenu
remov
multibas
cleavag
site
sequenc
insert
plasmid
plasmid
transfect
cell
line
togeth
plasmid
encod
intern
gene
viru
gener
appropri
nonpathogen
vaccin
seed
strain
vaccin
candid
express
target
haemagglutinin
highli
pathogen
virus
could
potenti
produc
within
week
emerg
event
recombin
virus
show
desir
properti
vaccin
formulationinclud
loss
egg
lethal
virul
infect
anim
modelshav
produc
although
one
attenu
recombin
viru
show
limit
neurovirul
mice
revers
genet
thu
capabl
gener
attenu
virus
pathogen
strain
suitabl
vaccin
product
limit
enhanc
biosecur
measur
use
preexist
equip
facil
also
possibl
prepar
panel
reassort
virus
vaccin
seed
candid
contain
target
gene
potenti
pandem
virus
advanc
specif
threat
howev
regulatori
safeti
legal
problem
overcom
technolog
use
vaccin
develop
mammalian
cell
line
eg
vero
cell
use
transfect
must
certifi
qualiti
human
vaccin
product
virus
gener
revers
genet
may
consid
genet
modifi
organ
impos
local
nation
safeti
regul
regard
research
develop
addit
intellectu
properti
right
revers
genet
technolog
held
licenc
may
need
grant
commerci
use
vaccin
inactiv
influenza
vaccin
poor
induc
cytotox
tcell
ctl
respons
aid
recoveri
influenza
infect
suggest
crossreact
immun
sever
influenza
viru
subtyp
could
induc
ctl
respons
conserv
epitop
intern
protein
dna
vaccin
integr
gene
sequenc
antigen
protein
interest
bacteri
plasmid
inocul
host
express
plasmid
dna
produc
antigen
natur
configur
like
stimul
neutralis
antibodi
undergo
hla
class
express
induc
ctl
respons
haemagglutininexpress
dna
vaccin
protect
mice
chicken
lethal
dose
viru
challeng
dna
vaccin
express
conserv
intern
protein
includ
nucleoprotein
give
partial
protect
mice
infect
intraderm
dna
influenza
vaccin
begin
clinic
evalu
iscomformul
vaccin
induc
ctl
respons
greater
longerlast
antibodi
respons
convent
vaccin
offer
broad
protect
viru
challeng
virul
virus
mice
iscom
vaccin
toler
human
be
induc
broad
ctl
rapid
humor
respons
mucos
deliveri
inactiv
influenza
vaccin
adjuv
modifi
heatlabil
enterotoxin
escherichia
coli
induc
bcelldepend
heterosubtyp
immun
lethal
viru
challeng
mice
absenc
antigen
match
vaccin
altern
vaccin
strategi
induc
crossreact
immun
iscom
dna
mucos
vaccin
may
provid
use
firstlin
defenc
emerg
pandem
strain
sinc
virus
multibas
haemagglutinin
cleavag
site
show
low
pathogen
avian
speci
may
grown
high
titr
egg
ahong
ahong
virus
capabl
human
infect
effect
vaccin
strategi
understand
rel
immunogen
crossprotect
induc
lineag
requir
although
infect
mice
group
virus
evok
detect
crossreact
neutralis
antibodi
protect
subsequ
rechalleng
homolog
heterolog
viru
lineag
wholeviru
vaccin
produc
crossreact
antibodi
respons
virus
protect
mice
rechalleng
either
viru
contrast
wholeviru
vaccin
induc
homolog
antibodi
titr
abl
protect
challeng
show
reduc
protect
efficaci
heterolog
lineag
singl
dose
vaccin
induc
adequ
immun
respons
mice
contrast
find
vaccin
requir
twodos
schedul
elicit
adequ
immun
respons
sinc
virus
grow
well
egg
reassort
produc
one
dose
inactiv
vaccin
protect
mice
challeng
two
dose
vaccin
increas
antibodi
respons
capabl
protect
mice
challeng
wholeviru
subunit
ahong
vaccin
clinic
evalu
uk
adult
randomli
assign
two
dose
administ
week
apart
g
haemagglutinin
content
although
well
toler
wholeviru
vaccin
reactiv
keep
vaccin
littl
detect
crossreact
immun
respons
antigen
distinct
viru
unpublish
find
prevaccin
serum
sampl
show
reactiv
neutralis
haemagglutinininhibit
suggest
preexist
crossreact
antibodi
exposur
earlier
haemagglutinin
unlik
influenza
circul
wide
uk
serolog
test
correl
reactiv
antibodi
respons
haemagglutinin
peopl
baselin
reactiv
born
thu
potenti
expos
period
circul
human
be
subject
immunolog
divid
naiv
prime
recipi
truli
naiv
subject
one
dose
either
vaccin
poorli
immunogen
although
wholeviru
vaccin
immunogen
subunit
vaccin
two
dose
still
left
signific
number
vaccine
serolog
respons
protect
threshold
tabl
among
prime
individu
one
dose
either
vaccin
boost
respons
fulfil
cpmp
criteria
sinc
second
dose
question
valu
preserv
limit
vaccin
suppli
first
wave
emerg
pandem
differ
schedul
differ
popul
could
consid
german
studi
among
yearold
report
one
dose
g
wholeviru
vaccin
ahong
capabl
fulfil
least
one
cpmp
criterion
second
dose
vaccin
significantli
improv
respons
howev
agerel
respons
effect
preexist
reactiv
analys
keep
experi
alumadjuv
allow
reduct
content
g
per
dose
maintain
immunogen
intranas
deliv
live
attenu
coldadapt
influenza
vaccin
elicit
system
local
mucos
immun
respons
display
protect
efficaci
attenu
coldadapt
strain
gener
reassort
wildtyp
viru
express
target
haemagglutinin
neuraminidas
coldadapt
donor
influenza
aann
donor
strain
cold
adapt
temperaturesensit
attenu
properti
associ
polygen
mutat
live
attenu
virus
display
high
level
phenotyp
genotyp
stabil
transmiss
close
seroneg
contact
attenu
arbor
coldadapt
recombin
virus
gener
seen
nonpathogen
mammalian
chicken
model
concern
gener
reassort
live
viru
vaccin
contain
avian
influenza
viru
coinfect
human
strain
possibl
spontan
genet
chang
may
limit
use
vaccin
interpandem
period
current
intramuscular
influenza
vaccin
effect
induc
rel
strainspecif
serum
haemagglutinationinhibit
igg
poor
stimul
secretori
iga
nasal
wash
fluid
secretori
iga
exhibit
potenti
heterotyp
crossreact
influenza
viru
strain
point
entri
live
attenu
viru
vaccin
may
offer
wider
protect
vaccinedrift
variant
could
advantag
pandem
underway
specif
influenza
antivir
agent
avail
earli
treatment
prophylaxi
influenza
adamantan
amantadin
rimantadin
avail
year
inhibit
strain
influenza
includ
nonhuman
subtyp
howev
rapid
emerg
transmiss
drugresist
viru
treatment
may
render
prophylaxi
ineffect
genet
basi
resist
seem
singl
aminoacid
substitut
viral
ion
channel
strain
isol
poultri
human
case
genotyp
chang
gene
associ
resist
suggest
agent
would
littl
clinic
valu
strain
becom
capabl
humantohuman
transmiss
neuraminidas
inhibitor
zanamivir
oseltamivir
effect
prevent
studi
highli
activ
broad
rang
influenza
virus
human
avian
origin
includ
amantadineresist
strain
although
strain
reduc
suscept
neuraminidas
inhibitor
isol
sequenti
passag
viru
presenc
drug
clinic
signific
resist
strain
yet
identifi
antivir
drug
may
benefit
protect
individu
essenti
servic
whilst
wait
effect
vaccin
prepar
howev
suppli
cost
issu
would
limit
effect
cours
pandem
suffici
larg
suppli
antivir
curb
pandem
influenza
would
requir
intern
need
robust
surveil
programm
human
anim
popul
share
inform
anim
human
surveil
system
surveil
inform
open
share
time
fashion
assess
potenti
threat
potenti
pandem
strain
come
anim
reservoir
improv
understand
antigen
molecular
associ
potenti
pandem
strain
subtyp
improv
understand
immunogen
drift
avian
influenza
strain
requir
abil
gener
broad
crossprotect
immun
desir
vaccin
candid
intellectu
properti
right
attenu
virus
produc
revers
genet
must
address
advanc
licenc
commerci
use
may
requir
vaccin
viru
candid
need
abl
grow
well
egg
approv
cell
cultur
improv
abil
respond
rapidli
emerg
threat
improv
understand
virul
determin
mammalian
model
abl
attenu
virus
use
vaccin
manufactur
safeti
viru
handl
worker
involv
prepar
vaccin
assess
approv
mammalian
cell
line
human
vaccin
qualiti
ensur
reagent
anim
sourc
transmiss
spongiform
encephalopathi
compliant
revers
genet
gener
virus
label
genet
modifi
organismsimpl
nation
local
regulatori
author
clinic
assess
vaccin
deriv
revers
genet
abil
organis
antigen
studi
rapidli
respons
emerg
threat
may
requir
prepar
approv
protocol
readili
adapt
improv
assess
antibodi
respons
avian
influenza
vaccin
establish
licens
criteria
standardis
assay
detect
neutralis
antibodi
avian
influenza
establish
correl
immun
protect
neutralis
antibodi
wholeviru
vaccin
immunogen
subunit
splitproduct
vaccin
immunolog
naiv
popul
two
dose
vaccin
requir
immunolog
naiv
popul
first
prime
second
boost
respons
prime
popul
singl
dose
vaccin
potenti
induc
respons
associ
protect
addit
adjuv
aluminium
salt
potenti
significantli
enhanc
immunogen
spare
antigen
use
avian
haemagglutinin
lesser
extent
seem
less
immunogen
peopl
assess
antibodi
respons
avian
influenza
may
requir
addit
serolog
method
standard
haemagglutinininhibit
test
potenti
crossreact
preexist
antibodi
complic
interpret
immun
respons
peopl
need
develop
understand
improv
vaccin
candid
enhanc
heterosubtyp
crossreact
protect
need
assess
vaccin
candid
advanc
pandem
identifi
difficulti
establish
dose
schedul
differ
popul
nation
stockpil
onset
event
would
requir
consider
expens
vaccin
like
remain
princip
mean
combat
pandem
influenza
although
pandem
plan
understand
greater
sinc
first
outbreak
abil
respond
rapidli
remain
less
optim
asian
epizoonot
outbreak
indic
urgent
need
vaccin
avian
influenza
virus
howev
regulatori
safeti
consider
confront
develop
panel
necessari
improv
understand
virul
determin
mammalian
system
abl
attenu
virus
select
appropri
safe
vaccin
strain
gener
broad
crossreact
nation
intern
author
must
urgent
confront
regulatori
issu
allow
product
clinic
assess
newli
gener
viru
vaccin
candid
import
observ
clinic
experi
vaccin
pandem
influenza
panel
despit
increas
reactogen
greater
immunogen
wholeviru
vaccin
could
benefici
pandem
vaccin
contain
avian
haemagglutinin
seem
less
immunogen
human
be
vaccin
base
haemagglutinin
whether
gener
event
associ
avian
subtyp
present
unclear
enhanc
alum
salt
may
provid
best
antigen
use
enhanc
immunogen
overal
far
clinic
trial
avian
influenza
vaccin
candid
given
disappoint
result
remain
seen
plasmidderiv
reversegenet
influenza
vaccin
perform
regulatori
hurdl
overcom
conflict
interest
